Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 3, 2015, Pages 108.e5-108.e13

  Palanisamy, Nallasivam ^a,b,c   Tsodikov, Alexi ^d   Yan, Wei ^a,b   Suleman, Khalid ^a,b   Rittmaster, Roger ^e   Lucia, Scott M ^f   Chinnaiyan, Arul M ^a,b,c   Fleshner, Neil ^g   Kunju, Lakshmi P ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Fluorescence in situ hybridization; Gene fusion; Immunohistochemistry; Prostate cancer; REDEEM trial

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR ETV5; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; E1A PROTEIN; ETV1 PROTEIN, HUMAN; ETV4 PROTEIN, HUMAN; ONCOPROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUSION; GENE REARRANGEMENT; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL; SPINK1 GENE; VERY ELDERLY; BACTERIAL ARTIFICIAL CHROMOSOME; BIOPSY; CLINICAL TRIAL (TOPIC); GENETICS; PROSTATIC NEOPLASMS;

5-ALPHA REDUCTASE INHIBITORS; ADENOVIRUS E1A PROTEINS; BIOPSY; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DUTASTERIDE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 85003049871     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.07.015     Document Type: Article

References (30)

1. Mehra R., Tomlins S.A., Shen R., Nadeem O., Wang L., Wei J.T., et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007, 20:538-544.
2. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
3. Palanisamy N., Ateeq B., Kalyana-Sundaram S., Pflueger D., Ramnarayanan K., Shankar S., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010, 16:793-798.
4. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
5. Tomlins S.A., Mehra R., Rhodes D.R., Smith L.R., Roulston D., Helgeson B.E., et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006, 66:3396-3400.
6. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
7. Tomlins S.A., Rhodes D.R., Yu J., Varambally S., Mehra R., Perner S., et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008, 13:519-528.
8. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
9. Ateeq B., Tomlins S.A., Laxman B., Asangani I.A., Cao Q., Cao X., et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011, 3:72ra17.
10. Baena E., Shao Z., Linn D.E., Glass K., Hamblen M.J., Fujiwara Y., et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013, 27:683-698.
11. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
12. Park K., Tomlins S.A., Mudaliar K.M., Chiu Y.L., Esgueva R., Mehra R., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
13. Attard G., Clark J., Ambroisine L., Fisher G., Kovacs G., Flohr P., et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27:253-263.
14. Demichelis F., Fall K., Perner S., Andren O., Schmidt F., Setlur S.R., et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchul waiting cohort. Oncogene 2007, 26:4596-4599.
15. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66:8337-8341.
16. Rajput A.B., Miller M.A., De Luca A., Boyd N., Leung S., Hurtado-Coll A., et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007, 60:1238-1243.
17. Nam R.K., Sugar L., Yang W., Srivastava S., Klotz L.H., Yang L.Y., et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007, 97:1690-1695.
18. Petrovics G., Liu A., Shaheduzzaman S., Furusato B., Sun C., Chen Y., et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005, 24:3847-3852.
19. Winnes M., Lissbrant E., Damber J.E., Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007, 17:1033-1036.
20. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
21. Andriole G.L., Bostwick D.G., Brawley O.W., Gomella L.G., Marberger M., Montorsi F., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-1202.
22. Fleshner N., Gomella L.G., Cookson M.S., Finelli A., Evans A., Taneja S.S., et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007, 28:763-769.
23. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24. PMID: 22277570 [PubMed - indexed for MEDLINE].
24. Han B., Mehra R., Dhanasekaran S.M., Yu J., Menon A., Lonigro R.J., et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008, 68:7629-7637.
25. Han B., Mehra R., Suleman K., Tomlins S.A., Wang L., Singhal N., et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 2009, 22:1176-1185.
26. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29:1228-1242. ISUP Grading Committee.
27. Han B., Mehra R., Lonigro R.J., Wang L., Suleman K., Menon A., et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009, 22:1083-1093.
28. Fleshner N.E. Dutasteride and active surveillance of low-risk prostate cancer. Lancet 2012, 379:1590.
29. Jhavar S., Brewer D., Edwards S., Kote-Jarai Z., Attard G., Clark J., et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009, 103:1256-1269.
30. Ateeq B., Vellaichamy A., Tomlins S.A., et al. Role of dutasteride in pre-clinical ETS fusion positive prostate cancer models. Prostate 2012, 72(14):1542-1549.